Skip to content

Tavaborole

    DEA Class; Rx

    Common Brand Names; Kerydin

    • Antifungal Topicals

    Oxaborole antifungal for onchomycosis of toenails
    Effective against Trichophyton rubrum or Trichophyton mentagrophytes
    Available as topical solution

    Indicated for onychomycosis of the toenail(s) due to Trichophyton rubrum or Trichophyton mentagrophytes

    Clean and dry nails prior to use; apply to completely cover nail surface and under tip of each nail being treated; allow solution to dry following application

    None reported by manufacturer

    Application site exfoliation (2.7%)

    Ingrown toenail (2.5%)

    Application site erythema (1.6%)

    Application site dermatitis (1.3%)

    Hypersensitivity, contact allergy

    Not for oral, ophthalmic, or intravaginal use

    Avoid contact with eyes, mouth, vagina, or skin immediately surrounding treated nail; wipe away excess solution from surrounding skin

    Product is flammable; avoid use near heat or open flame

    There are no available data on use in pregnant women to inform a drug associated risk for major birth defects, miscarriage or adverse maternal or fetal outcomes

    There is no information available on presence in human milk, effects on breastfed infant or on milk production in women who are breastfeeding

    Adults

    Specific maximum dosage information not available.

    Geriatric

    Specific maximum dosage information not available.

    Adolescents

    Specific maximum dosage information not available.

    Children

    6 to 12 years: Specific maximum dosage information not available.
    1 to 5 years: Safety and efficacy have not been established.

    Infants

    Safety and efficacy have not been established.

    Neonates

    Safety and efficacy have not been established.

    Tavaborole

    solution

    • 43.5mg/mL (0.5%)